IP Library Granted Patent US 7,863,222
Granted Patent B2
US 7,863,222 · App. 12/221,325 · Granted Jan 4, 2011

shRNA library

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,863,222
App. No.
12/221,325
Granted
Jan 4, 2011
Kind
B2
Abstract

As noted above, certain aspects of this disclosure relate to a library of nucleic acid vectors, as well as a method for making the same. In certain embodiments, the library of nucleic acid vectors comprises: a plurality of nucleic acid molecules of the following formula: S 1 —R—S 2 wherein, in each nucleic acid of the plurality: S 1 and S 2 are each at least 15 nucleotides in length; S 1 and S 2 are complementary to each other along their entire length; either S 1 or S 2 is complementary along its entire length to a sequence in eukaryotic mRNA; and R is a six base recognition site for a restriction endonuclease; and wherein S 1 and S 2 vary in nucleotide sequence between different members of the plurality. A method for amplifying a circular nucleic acid is also provided.

Claims (25)

1. A method of producing a library of nucleic acids, comprising:

a) ligating a first double stranded adaptor comprising a first and a second type IIs restriction enzyme recognition sites to blunt end fragments to produce first adaptor-ligated fragments;

b) digesting said adaptor-ligated fragments with said first type IIs restriction enzyme to produce digested fragments comprising said first double stranded adaptor and said second type IIs restriction enzyme recognition site;

c) ligating a first hairpin adaptor comprising restriction enzyme recognition sites to said digested fragments to produce second adaptor-ligated fragments;

d) digesting said second adaptor-ligated fragments with said second type IIs restriction enzyme to produce a population of hairpin-containing digestion products;

e) ligating a second hairpin adaptor to said population of hairpin products to produce a population of circular nucleic acid molecules;

f) amplifying said population of circular nucleic acid molecules using rolling circle amplification to produce a population of linear double stranded nucleic acids;

g) digesting said population of linear double stranded nucleic acids with restriction enzymes that recognizes said restriction enzyme recognition sites of said first hairpin adaptor to produce a population of clonable fragments comprising nucleic acids of the formula:

S 1 -T-S 2 ,

wherein: S 1 and S 2 are complementary to each other and are each at least 15 nucleotides in length and T is an amplification product of said second hairpin adaptor and comprises two six base recognition sites for a second restriction endonuclease;

h) ligating said clonable fragments into a vector to produce a population of circular vectors;

i) digesting said population of circular vectors with said second restriction enzyme to produce digested vectors; and

j) intramolecularly religating said digested vectors to produce said library of nucleic acids vectors comprising a plurality of nucleic acid molecules of the formula:

S 1 —R—S 2 ,

wherein S1 and S2 are as set forth above, and R is a six base recognition site for said second restriction endonuclease.

2. The method of claim 1 , wherein said target double stranded nucleic acid is double stranded cDNA made from mRNA isolated from a mammalian cell.

3. The method of claim 1 , wherein said method comprises, before said ligating step: digesting said sample comprising target double stranded DNA with a plurality of different blunt end restriction enzymes that cleave at different sites to produce said blunt end fragments.

4. The method of claim 1 , wherein said first double stranded adaptor is a hairpin adaptor.

5. The method of claim 1 , wherein digesting step g) is done by digesting said population of linear double stranded nucleic acids with a type II restriction enzyme and a type IIs restriction enzyme that cleave at sites present within said second hairpin.

6. The method of claim 1 , wherein said amplifying step f) is done by:

combining said population of circular nucleic acid molecules, a primer that anneals to said population of circular nucleic acid molecules and a Ø29 polymerase under polymerization conditions to produce a single-stranded template;

denaturing said single stranded template to make a denatured template;

rapidly cooling said denatured template; and

combining said denatured template, a primer that anneals to said denatured template and a proofreading DNA polymerase under polymerization conditions to produce said population of linear nucleic acids.

7. The method of claim 6 , wherein said method comprises transforming cells with said population of circular vectors of step h), and re-isolating said population of circular vectors from said cells prior to step i).

Assignments (3)
SECURITY INTEREST Recorded May 8, 2026
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 075576/0880 →
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2008
From: PAYAN, DONALD G.; SHEN, MARY; YU, SIMON; KINSELLA, TODD M.; HITOSHI, YASUMICHI
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 021733/0130 →